TriSalus Life Sciences Expects Sales To Grow In Excess Of 50% In 2024; Says Currently In The Process Of Obtaining Additional Liquidity To Fund Operations Through 2024
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences anticipates over 50% sales growth in 2024 and is seeking additional liquidity to support operations through the year. It expects to report $11.8 million in cash and equivalents by the end of 2023, with sufficient liquidity into Q2 2024.

March 11, 2024 | 9:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TriSalus Life Sciences expects over 50% sales growth in 2024 and is working on securing additional liquidity to fund operations through the year. It anticipates $11.8 million in cash and equivalents by end of 2023, ensuring liquidity into Q2 2024.
The anticipated sales growth of over 50% in 2024 for TriSalus Life Sciences is a strong positive signal for investors, indicating potential revenue growth and operational expansion. The company's efforts to secure additional liquidity further support its financial stability and operational continuity, positively impacting investor confidence and potentially the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100